toripalimab

Ask MedXY AI

Latest news

Tag

newsNon-Small Cell Lung Cancerperioperative immunotherapy

Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial

By MedXY|Jul 20, 2026

This post hoc analysis of the Neotorch phase 3 trial demonstrates that adding toripalimab to chemotherapy perioperatively in stage III resectable NSCLC improves tumor and nodal downstaging, reduces surgery cancellation, and significantly en

newsAcral Melanomaclinical trial

Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial

By MedXY|Jan 6, 2026

The Phase 3 MELATORCH trial demonstrates that toripalimab significantly improves progression-free survival (PFS) compared to dacarbazine in patients with advanced acral melanoma, reducing the risk of progression or death by 29.2% with a man

Clinical Updatesbevacizumabhepatocellular carcinoma

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

By MedXY|Oct 1, 2025

The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.